Session » Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 385

Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 387

Early Mortality in IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 381

Effect of Vitamin D Supplementation on Calcium Levels in Patients with Sarcoidosis: A Retrospective Analysis

9:00AM-11:00AM: Abstract Number: 375

Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center

9:00AM-11:00AM: Abstract Number: 386

Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain

9:00AM-11:00AM: Abstract Number: 376

Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 369

Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review

9:00AM-11:00AM: Abstract Number: 382

Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis

9:00AM-11:00AM: Abstract Number: 379

Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group

9:00AM-11:00AM: Abstract Number: 377

Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition

9:00AM-11:00AM: Abstract Number: 372

Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience

9:00AM-11:00AM: Abstract Number: 368

Practice Patterns in Bone Health and Vitamin D Management in Sarcoidosis: A Survey of Physicians Who Manage Sarcoidosis

9:00AM-11:00AM: Abstract Number: 384

Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease

9:00AM-11:00AM: Abstract Number: 373

Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 383

Retroperitoneal Fibrosis- a Single Center Experience

9:00AM-11:00AM: Abstract Number: 371

Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 380

Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution

9:00AM-11:00AM: Abstract Number: 378

Systemic and Ocular Sarcoidosis Study of 381 Patients from a Single Universitary Centre in the Last 20 Years

9:00AM-11:00AM: Abstract Number: 374

The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 367

Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience

9:00AM-11:00AM: Abstract Number: 370

Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].